Literature DB >> 27134869

Adherence to Hospital Antibiotic Policy for Treatment of Escherichia coli ESBL in Urine.

R Someshwaran1, K Gnana Prakash2, Shreeram A Deshpande1, Anbu N Aravazhi3.   

Abstract

INTRODUCTION: Escherichia coli are the most common uropathogen worldwide accounting for 80% of the Urinary Tract Infections (UTIs). Nosocomial infections caused by Multi-drug resistant Gram negative bacteria expressing Extended Spectrum β Lactamase enzyme, pose a serious therapeutic challenge to clinicians due to limited therapeutic options. Stringent adherence to Hospital Antibiotic Policy in treating Urinary Escherichia coli ESBLs is a borne necessity. AIM: A clinical audit was undertaken in the form of a cross-sectional study to evaluate the compliance on appropriate antibiotic prescription and strict adherence to Hospital Antibiotic Policy for therapeutic management of the patients infected with urinary Escherichia coli ESBL producers.
MATERIALS AND METHODS: A cross-sectional medical audit on adherence to treatment of Escherichia coli ESBL producers from in-patients diagnosed to have urinary tract infections for a duration of 7 months was conducted as a prospective study. Clinical data, culture and sensitivity reports of the patient diagnosed with urinary Escherichia coli ESBLs were compared with the treatment chart to ensure strict adherence to hospital antibiotic policy for appropriate therapy by physicians. Data were analysed using IBM SPSS version 20 software.
RESULTS: The incidence of uncomplicated cystitis, pyelonephritis and complicated pyelonephritis cases were 65.24% (107 out of 164), 20.7% (34 out of 164) and 14.02% (23 out of 164) respectively. Resistance to individual fluoroquinolones like norfloxacin, ciprofloxacin and ofloxacin were found to be 60%, 59% and 47.5% respectively. As per hospital antibiotic policy, fluoroquinolones were prescribed in only 23% of the patients for the treatment of urinary Escherichia coli ESBLs.
CONCLUSION: Irrational utilization of antibiotics and non-adherence to antibiotic policy could have been the significant risk factors for drug resistance. Optimized antibiotic use, Microbiology laboratory support and periodic antibiotic audit led by effective infection control team would hasten the development of drug resistance.

Entities:  

Keywords:  Drug resistance; Fluoroquinolones; Medical audit; Morbidity and mortality; Rational antibiotic use; Treatment outcome

Year:  2016        PMID: 27134869      PMCID: PMC4843255          DOI: 10.7860/JCDR/2016/16084.7382

Source DB:  PubMed          Journal:  J Clin Diagn Res        ISSN: 0973-709X


  25 in total

1.  A survey of inpatient antibiotic use in a teaching hospital.

Authors:  B Till; L Williams; S P Oliver; P I Pillans
Journal:  S Afr Med J       Date:  1991-07-06

Review 2.  Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria.

Authors:  Ann Pallett; Kieran Hand
Journal:  J Antimicrob Chemother       Date:  2010-11       Impact factor: 5.790

Review 3.  International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases.

Authors:  Kalpana Gupta; Thomas M Hooton; Kurt G Naber; Björn Wullt; Richard Colgan; Loren G Miller; Gregory J Moran; Lindsay E Nicolle; Raul Raz; Anthony J Schaeffer; David E Soper
Journal:  Clin Infect Dis       Date:  2011-03-01       Impact factor: 9.079

Review 4.  Control of antimicrobial resistance in the health care system.

Authors:  J E McGowan; F C Tenover
Journal:  Infect Dis Clin North Am       Date:  1997-06       Impact factor: 5.982

5.  Multicenter evaluation of antimicrobial resistance to six broad-spectrum beta-lactams in Colombia: comparison of data from 1997 and 1998 using the Etest method. The Colombian Antimicrobial Resistance Study Group.

Authors:  M A Pfaller; R N Jones; G V Doern; J C Salazar
Journal:  Diagn Microbiol Infect Dis       Date:  1999-11       Impact factor: 2.803

6.  Oral treatment options for ambulatory patients with urinary tract infections caused by extended-spectrum-beta-lactamase-producing Escherichia coli.

Authors:  Simon Auer; Alexandra Wojna; Markus Hell
Journal:  Antimicrob Agents Chemother       Date:  2010-06-28       Impact factor: 5.191

Review 7.  ESCMID guidelines for the management of the infection control measures to reduce transmission of multidrug-resistant Gram-negative bacteria in hospitalized patients.

Authors:  E Tacconelli; M A Cataldo; S J Dancer; G De Angelis; M Falcone; U Frank; G Kahlmeter; A Pan; N Petrosillo; J Rodríguez-Baño; N Singh; M Venditti; D S Yokoe; B Cookson
Journal:  Clin Microbiol Infect       Date:  2014-01       Impact factor: 8.067

8.  Resistance to third-generation cephalosporins in Barbados.

Authors:  P N Levett; H A Holt; A P McGowan
Journal:  West Indian Med J       Date:  1993-06       Impact factor: 0.171

9.  Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae bloodstream infection: risk factors and clinical outcome.

Authors:  Bin Du; Yun Long; Hongzhong Liu; Dechang Chen; Dawei Liu; Yingchun Xu; Xiuli Xie
Journal:  Intensive Care Med       Date:  2002-10-17       Impact factor: 17.440

Review 10.  beta-Lactam resistance in gram-negative bacteria: global trends and clinical impact.

Authors:  C C Sanders; W E Sanders
Journal:  Clin Infect Dis       Date:  1992-11       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.